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Alpha-hexachlorocyclohexane (alpha-HCH) is one of eight structural isomers that have been used
worldwide as insecticides. Although no longer produced or used agriculturally in the United States,
exposure to HCH isomers is of continuing concern due to legacy usage and persistence in the
environment. The U.S. Environmental Protection Agency (EPA) classiﬁes alpha-HCH as a probable
human carcinogen and provides a slope factor of 6.3 (mg/kg-day)1 for the compound, based on
hepatic nodules and hepatocellular carcinomas observed in male mice and derived using a default
linear approach for modeling carcinogens. EPA's evaluation, last updated in 1993, does not consider
more recently available guidance that allows for the incorporation of mode of action (MOA) for
determining a compound's dose-response. Contrary to the linear approach assumed by EPA, the
available data indicate that alpha-HCH exhibits carcinogenicity via an MOA that yields a nonlinear,
threshold dose-response. In our analysis, we conducted an MOA evaluation and dose-response
analysis for alpha-HCHeinduced liver carcinogenesis. We concluded that alpha-HCH causes liver
tumors in rats and mice through an MOA involving increased promotion of cell growth, or mito-
genesis. Based on these ﬁndings, we developed a threshold, cancer-based, reference dose (RfD) for
alpha-HCH.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alpha-hexachlorocyclohexane (alpha-HCH) is one of eight
structural isomers that have been used worldwide as in-
secticides. It is a component of technical-grade HCH and a
byproduct of gamma-HCH (commonly called Lindane) synthesis.
Prior to the late 1970s, technical-grade HCH, a mixture of the
alpha, beta, gamma, delta, and epsilon isomers, was used on a
wide variety of food crops, seeds, and ornamental plants. After
that time only the gamma isomer, the isomer with the mostBroadway, Suite 1601, New York,
Bradley).
Inc. This is an open access article usigniﬁcant insecticidal activity, was used. HCH production and
use have declined over time and the ﬁnal remaining approved
uses of Lindane in the United States were cancelled by the U.S.
Environmental Protection Agency (EPA) in 2006. Lindane has
similarly been phased out in Europe, Mexico, and Canada,
although it is still produced in India and possibly Russia (USEPA,
2006).
Although no longer produced or used agriculturally in the
United States, exposure to HCH isomers is of continuing concern
due to the historical levels of HCH use, their persistence in theNY 10006, USA.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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for inclusion on the National Priority List (NPL; i.e., Superfund)
(ATSDR, 2005). EPA recently included alpha-HCH on its fourth
Draft Contaminant Candidate List (CCL 4) (USEPA, 2015a), and
proposed that its occurrence in public water supplies be moni-
tored as part of the 4th Unregulated Contaminant Monitoring Rule
(UCMR) program (USEPA, 2015b). By way of the UCMR alpha-HCH
may require regulation under the Safe Water Drinking Act (SWDA)
in the future.
In its Integrated Risk Information System (IRIS), EPA classiﬁes
alpha-HCH as a probable human carcinogen and provides a slope
factor of 6.3 (mg/kg-day)1 for the compound, based on hepatic
nodules and hepatocellular carcinomas observed in male mice
(Ito et al., 1973a). The slope factor was derived using EPA's
default, linear low-dose extrapolation approach for modeling
carcinogens. Last updated in 1993, EPA's evaluation does not
consider more recently available guidance (e.g., USEPA, 2005)
that allows for the incorporation of mode of action (MOA) for
determining a compound's dose-response. Contrary to the linear
approach assumed by EPA in their last evaluation of alpha-HCH,
the available data indicate that alpha-HCH exhibits carcinoge-
nicity via an MOA that yields a nonlinear, threshold dose-
response.
The potential for alpha-HCH to cause carcinogenic effects in
humans is not well studied, and animal data provide the primary
basis with which to assess effects. Long-term dosing with high
doses of alpha-HCH has been found to induce hyperplastic nodules
and carcinomas in the livers of rats and mice (Hanada et al., 1973;
Ito et al., 1973a,b; Ito et al., 1975; Ito et al. 1976; Nagasaki et al.,
1975; Schulte-Hermann and Parzefall, 1981; Tryphonas and Iver-
son, 1983). Lower-doses of alpha-HCH have not been found to
induce tumor formation (Hanada et al., 1973; Ito et al., 1973a,b; Ito
et al., 1975). Alpha-HCH does not consistently demonstrate muta-
genicity in short-term assays (Masuda et al., 2001;
Puatanachokchai et al., 2006; Schroter et al., 1987; Fukushima
et al., 2005; RIVM, 2001; USEPA, 1987) and therefore has been
classiﬁed as a nongenotoxic carcinogen. Initiation-promotion
studies have further demonstrated that alpha-HCH does not
initiate carcinogenic activity but causes tumor formation via pro-
motion of preneoplastic lesions (Schroter et al., 1987; Siglin et al.,
1995). Patterns that suggest a growth-promoting MOA, including
long time-to-tumor and reversibility of tumor formation upon
cessation of exposure (USEPA, 2005), have also been demonstrated
for alpha-HCH (Ito et al., 1976; Schulte-Hermann and Parzefall,
1981; Tryphonas and Iverson, 1983).
Dose-response data for alpha-HCH further suggest the exis-
tence of a threshold below which there is no increased risk of
cancer following alpha-HCH exposure. Ito et al. (1973a,b)
observed increases in carcinomas in the livers of mice dosed
with greater than or equal to 250 ppm (i.e., 37 mg/kg-day) alpha-
HCH, but no increase in the livers of animals dosed with 50 and
100 ppm alpha-HCH. Ito et al. (1975) observed carcinomas in the
liver of rats dosed with 1000 and 1500 ppm alpha-HCH, but no
increase in rats dosed with 500 ppm alpha-HCH. Threshold and
hormetic responses have also been observed for known pre-
cursors to tumor formation. For example, Puatanachokchai et al.
(2006) showed a hormetic dose-response for the development of
preneoplastic lesions in the liver. Speciﬁcally, the number and
size of preneoplastic lesions increased in initiated rats adminis-
tered higher doses of alpha-HCH. Rats initiated withdiethylnitrosamine (DEN) and dosed with 0.05 ppm alpha-HCH
had statistically fewer and smaller preneoplastic lesions in the
liver compared to rats initiated with DEN and dosed with
0.01 ppm alpha-HCH. Moreover, it is generally recognized that
nongenotoxic carcinogens exhibit a threshold below which there
is no increased risk of cancer (Butterworth, 2006; Melnick et al.,
1996; Williams, 2008).
In this analysis, we conducted an MOA evaluation and dose-
response analysis of the alpha-HCH data set. We used guidance
available from EPA and the International Programme on Chem-
ical Safety (IPCS) on evaluating the relevance of animal tumors
for human health risk assessment (USEPA, 2005; Meek et al.,
2003), to frame our analysis. We used the body of literature on
alpha-HCH carcinogenicity and liver toxicity to describe the
progression of biological events that occurs with the formation
of liver tumors in rats and mice, the underlying dose-response of
those events, and the relevance of the effect for humans. The
results of the MOA analysis were used to select the modeling
scheme (e.g., linear or nonlinear/threshold) for the dose-
response analysis. Based on the ﬁndings of the MOA analysis,
we developed a threshold, cancer-based reference dose (RfD) for
alpha-HCH.
2. Methods
2.1. MOA analysis
EPA's guidelines for carcinogen risk assessment (2005)
emphasize the use of MOA in the assessment of potential car-
cinogens. Speciﬁcally, the guidelines recognize that understand-
ing the MOA may provide important insight for determining
whether a cancer hazard exists, and may help inform appropriate
consideration of the dose-response relationship below the range
of observable tumor response. An MOA for a toxicological effect is
deﬁned as a biologically plausible sequence of key events, start-
ing with interaction of an agent with a cell, proceeding through
biochemical, functional, and anatomical changes, that ultimately
results in cancer formation or noncancer effects (Boobis et al.,
2006, 2009; Meek, 2008; USEPA, 2005). A key event is an
empirically observable precursor step that is itself a necessary
element of the MOA or is a biologically based marker for such an
element (USEPA, 2005). This deﬁnition is broader than that
described in Andersen et al. (2014), which limits the deﬁnition of
a key event to an empirically observable precursor step and de-
ﬁnes any reliable indicators or markers of key events as “asso-
ciative events.” The former deﬁnition was applied for this
evaluation.
We identiﬁed an MOA, including key events (based on EPA's
deﬁnition), for alpha-HCH liver carcinogenesis. The MOA and its
human relevance was evaluated under the MOA framework pro-
posed by EPA (USEPA, 2005), based in part on Meek et al. (2003),
and applied and discussed by others (e.g., Boobis et al., 2009;
Butterworth, 2006; Meek, 2008; Elcombe et al., 2014). The two
central questions of the MOA evaluation were (1) is the weight of
evidence (WOE) sufﬁcient to establish an MOA in animals?, and (2)
is the MOA relevant to humans? In addition, we evaluated the
biochemical and physiological processes underlying each key
event, and available dose-response data for each key event, to
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used in the dose-response assessment.
We evaluated our hypothesized MOA in animals by using the
modiﬁed Hill criteria, including strength, consistency, speciﬁcity of
association; dose-response concordance; temporal relationship;
and biological plausibility and coherence (USEPA, 2005). The pos-
sibility that an alternative MOA is responsible for liver carcinoge-
nicity in animals was also evaluated.
We also assessed the relevance of the MOA for humans. Using
the human relevance framework (HRF) proposed by Meek et al.
(2003), two categories of information were evaluated to inform
this analysis: (1) alpha-HCHespeciﬁc data, and (2) generic in-
formation pertinent to each key event but not derived from
alpha-HCH speciﬁcally. Both qualitative and quantitative differ-
ences in key events between animals and humans were consid-
ered.2.2. Dose-response evaluation and toxicity criterion development
2.2.1. General approach
The results of the MOA evaluation were used to determine the
dose-response scheme selected for establishing a toxicity crite-
rion for alpha-HCH. When a chemical acts via an MOA that is
sufﬁciently established in animals, exhibits a threshold dose-
response, and is relevant to humans, EPA guidance (USEPA,
2005) allows for a nonlinear modeling approach to quantita-
tively characterize cancer risk. Based on our evaluation of the
MOA for liver carcinogenicity in rats and mice, we followed EPA's
cancer guidelines (USEPA, 2005) for modeling nonlinear cancer
dose-response.
Deﬁning a point of departure (POD) for the critical effect is the
ﬁrst step in deriving a toxicity criterion. EPA deﬁnes the critical
effect as the ﬁrst adverse effect, or its known precursor, that oc-
curs in the most sensitive species as the dose rate of an agent
increases (USEPA, 2015c). The POD can be the lower bound on
dose for an estimated incidence, a change in response level from a
dose-response model, or a no-observed-adverse-effect level
(NOAEL) or lowest-observed-adverse-effect level (LOAEL) for an
observed incidence or change in level of response. We selected
candidate endpoints for the POD by identifying toxicological
endpoints from the available experimental studies that appropri-
ately reﬂect or are related to liver tumors. We limited candidate
endpoints to those evaluated in studies of subchronic or chronic
duration. Our evaluation focused on low-dose studies, deﬁned for
this evaluation as studies with at least one treatment dose of
10 mg/kg bw-day or less.
Benchmark response (BMR) levels, NOAELs, and LOAELs were all
considered in the POD determination. Although use of BMRs offers
some advantages over NOAELs or LOAELs, which are limited to
experimental treatment doses, not all data types and sets are
amenable to benchmark dose (BMD)modeling (USEPA,1995, 2012).
By considering each of these types of response levels, data that
were not suitable for BMD modeling were still considered in the
determination of the POD.
Average daily doses were calculated, where necessary from
dietary doses, using body weight and food consumption data
included in the study, or in the absence of such data, default
values available from USEPA (1988). Average daily animal doses(mg/kg-day) were then converted to human equivalent doses
(HEDs) on the basis of three-quarters body weight scaling, which
is equivalent to mg/kg¾-d (milligrams of the agent normalized by
the three-quarter power of body weight per day) (USEPA, 2011).
The default human body weight of 80 kg (USEPA, 2014) was
assumed:
Thehuman equivalent dose ðHED; mg=kgdayÞ ¼ animal dose ðmg=kgdayÞ
ðBWh=BWaÞ1
=
4
2.2.2. BMD modeling
To model dose response we used EPA's benchmark dose
software (BMDS; version 2.6.0.86) (USEPA, 2012). For the low-
dose studies, absolute and relative liver weights, DNA content,
foci area, and foci number were selected as candidate endpoints
for the POD, where data suitable for the BMDS program were
available. For continuous data, EPA's standard approach is to
deﬁne the BMR based on the level of change in the endpoint at
which the effect becomes biologically signiﬁcant (USEPA, 2012).
When it is not known at what level a response is considered to be
adverse, a change in the mean equal to one standard deviation
from the control mean may be used as the BMR (USEPA, 2012).
For the modeled data, a 10% increase was used as the BMR for
absolute and relative liver weight, while the BMR was set at 1
standard deviation from the control mean for DNA content, foci
area, and foci number. The 95% lower conﬁdence limit on the
BMD (BMDL) at the deﬁned BMR was considered the POD. The
MOA established for alpha-HCH does not prescribe any particular
dose-response model for selection, nor does it reject any.
Therefore, all available models for continuous data that support a
nonlinear endpoint within the BMDS programwere run (e.g., Hill,
exponential, power, polynomial) to aid in selecting a model that
best describes the data. Default program parameters were used,
with the exception of constant variance. When the statistical test
for variance failed, a nonconstant variance approach was
employed. The p-value to determine test acceptance or rejection
was set at 0.1 in accordance with EPA recommendations (USEPA,
2012). Model ﬁt was assessed considering p-value for goodness-
of-ﬁt, the Akaike information criterion (AIC) value, scaled re-
siduals near the range of the BMD, and visual inspection of the
dose-response curves in the low-dose range. Among the models
with adequate ﬁt to the data, we selected the model with the
lowest AIC as the basis of the BMDL if the BMDLs were within a
factor of three. If the BMDLs for models with adequate data ﬁt
were not within a factor of 3, we selected the model with the
lowest BMDL (USEPA, 2012).
2.2.3. Selection of NOAELs and LOAELs
In determining the POD, we also considered the lowest statis-
tically signiﬁcant NOAEL or LOAEL among relevant endpoints.
Where available, NOAELs were preferred and selected. For studies
and endpoints for which a NOAEL was not available LOAELs were
considered. Only statistically signiﬁcant effect levels (i.e., p < 0.05)
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niﬁcant but not part of an overall dose-response trend were not
selected for the LOAEL.
2.2.4. Uncertainty factors
The last step in determining an RfD is selecting and applying
uncertainty factors (UFs) to the POD to account for uncertainties
associated with the available data and variability between the test
species and sensitive human populations. We selected and applied
the following UFs commonly used in human health risk assess-
ment: (1) intraspecies extrapolation factor (intended to account for
the variation in sensitivity among members of the human popu-
lation), (2) interspecies extrapolation factor (intended to account
for uncertainty involved in extrapolating from animal data to hu-
man data), (3) subchronic-to-chronic duration factor (intended to
account for uncertainty involved in extrapolating from less-than-
chronic NOAELs to chronic), (4) LOAEL-to-NOAEL factor (intended
to account for the uncertainty involved in extrapolating from a
LOAEL to a NOAEL), and (5) database factor (intended to account for
the potential of deriving an underprotective RfD as the result of an
incomplete characterization of the chemical's toxicity). We also
considered the need for any additional modifying factors (MFs) to
account for scientiﬁc uncertainties not explicitly treated by other
UFs.
3. Results
3.1. MOA evaluation
3.1.1. Hypothesized MOA
Using an MOA framework, the WOE supports a nonlinear dose-
response with alpha-HCH causing liver tumors in rats and mice
through an MOA involving increased promotion of cell growth, or
mitogenesis. The key events underlying its carcinogenic action are:
(1) absorption of alpha-HCH in the liver, (2) cytochrome P450 (CYP;
P450) induction via receptor-mediated mechanisms, (3) increased
cell proliferation, ultimately resulting in (4) benign and malignant
tumor formation. Table 1 summarizes the available primary liter-
ature for alpha-HCH toxicology (aside from mutagenicity studies,
which are presented in Table 3). Table 2 summarizes the evaluation
of this MOA against the modiﬁed Hill criteria.
3.1.1.1. Key event 1 e absorption of Alpha-HCH in the liver.
Alpha-HCH is readily absorbed into the liver and has been detected
in liver and other tissues after subchronic or chronic dietary
exposure (Fitzhugh et al., 1950; Schroter et al., 1987). Alpha-HCH
has also been isolated from mouse liver deoxyribonucleic acid
(DNA), ribonucleic acid (RNA), and/or protein following a single
oral bolus or intraperitoneal dose (Iverson et al., 1984; Sagelsdorff
et al., 1983). The detection of alpha-HCH in the liver supports an
association between exposure and the development of liver tu-
mors.
3.1.1.2. Key event 2 e cytochrome P450 induction via receptor-
mediated mechanisms. Liver tumor formation in rodents afterexposure to nongenotoxic agents is often associated with the se-
lective induction of hepatic microsomal P450 enzymes. This in-
duction is triggered through activation of receptor-mediated
mechanisms that lead to enhanced gene transcription. Important
nuclear receptors involved in the induction of CYP1A, 2B, 3A, and
4A enzymes are, respectively, the aryl hydrocarbon, constitutive
androstane receptor (CAR), the pregnane X receptor (PXR), and the
peroxisome proliferatoreactivated receptor (PPAR-alpha). Activa-
tion of these receptors in rodents produces a cascade of alterations
in gene transcription that leads to increased hepatocellular prolif-
eration, a critical event in the development of liver tumors
(Elcombe et al., 2014).
Upon absorption in the liver, alpha-HCH induces hepatic P450
enzymes. Increased P450 protein and isozyme activity are consis-
tently demonstrated in rats exposed to alpha-HCH, as shown in
studies of varying experimental design (Masuda et al., 2001;
Puatanachokchai et al., 2006; Schroter et al., 1987; Schulte-
Hermann and Parzefall, 1980, 1981; Sumida et al., 2007; Werle-
Schneider et al., 2006). P450 activity and protein are increased in
treated systems, with CYP2B and 3A showing the greatest increases
(Masuda et al., 2001; Puatanachokchai et al., 2006). Induction of
CYP2B and 3A indicate activation of the orphan nuclear receptors
CAR and/or PXR. Both CAR and PXR heterodimerize with the reti-
noid X receptor (RXR) to regulate transcription. Many of the mol-
ecules that can activate CAR may also activate PXR, producing
reciprocal activation of CYP2B and 3A genes (Moore et al., 2000).
Nicotinamide adenine dinucleotide phosphate (NADPH) P450
reductase activity has been shown to increase alongwith total P450
levels following alpha-HCH exposure in rats (Barros et al., 1991;
Puatanachokchai et al., 2006).
Increases in P450 activity and protein are both dose- and time-
dependent (Masuda et al., 2001; Puatanachokchai et al., 2006).
Masuda et al. (2001) report increased CYP2B1 and CYP3A2 protein
expression and activity in animals dosed with greater than 15 ppm
alpha-HCH. Puatanachokchai et al. (2006) observed a hormetic
dose-response curve for HCH-mediated total P450 and P450
reductase levels, with signiﬁcant decreases in rats initiated with
DEN and dosedwith 0.05 ppm alpha-HCH, and signiﬁcant increases
in rats initiated with DEN and treated with 500 ppm alpha-HCH.
Increases in CYP isoform activity diminish following cessation of
exposure, supporting the role of alpha-HCH as a tumor promoter,
for which an ultimate tumorigenic effect is due to sustained cellular
change mediated by sustained exposure (Schulte-Hermann and
Parzefall, 1981).
P450 induction is a threshold-based, receptor-mediated process
that is regulated largely at the level of transcription. CYP inducers
normally bind as ligands to the nuclear receptor; however, CAR can
be activated without direct ligand binding by an indirect or ligand-
independent mechanism. This indirect mechanism involves a
dephosphorylation reaction that signals through the epidermal
growth factor receptor and leads to the nuclear translocation of
CAR. Regardless of whether nuclear receptors are activated through
direct or indirect mechanisms, the effectiveness of receptor-
mediated transcription induction depends on an array of factors
such as the afﬁnity of the xenobiotic for receptors and the presence
of co-activators or co-repressors (Kohn and Melnick, 2002). In such
a multifactorial process there are doses of inducer at which no
measurable response would occur, as has been demonstrated for
alpha-HCH.
Table 1
Studies evaluating alpha-HCH carcinogenicity and mode of action.
Reference Species, Sex Study Design Summary of Findings Study Limitations
Angsubhakorn
et al. (1981)
Rat (Buffalo), male Duration: up to 35 weeks exposure;
interim sacriﬁces and 30 week
recovery
Sample Size: 3-8/group
Route: dietary, ad libitum
Dose Levels: 0, 500 ppm
Centrilobular hypertrophy observed in treated
animals beginning after week 5 (incidence of 4/
4) and continuing throughout treatment period
(incidence of 5/5 after 35 weeks). Treatment-
related centrilobular hypertrophy regressed:
incidence of 0/7 after the recovery period.
Incidence of foci of cellular alterations was 1/5
after 35 weeks and 1/7 after 35 weeks plus 30
week recovery. No nodules or HCC observed.
Small sample size. Only males evaluated. Only
one dose level evaluated. Mortality/general
toxicity not reported. No statistical evaluation.
Barros et al. (1991) Rat (Wistar), male Duration: 15 or 30 days
Sample Size: 6-22/group
Route: dietary, ad libitum
Dose Levels: 0, 20 ppm
Increased total P450 levels at 15 days; further
increase at 30 days (both signiﬁcant).
Increased P450 reductase at 30 days. Increased
TBARS formation in liver homogenates and
microsomes after 15 and 30 days. Increased
microsomal superoxide production at 15 days;
further increase at 30 days. Increased SOD
activity at 15 days; decreased at 30 days relative
to 15 days (but higher than control). Increased
glutathione reductase at 30 days; increased
catalase at 15 and 30 days. All changes were
statistically signiﬁcant andwere generally time-
dependent.
No microscopic changes.
Small sample size. Only one dose level
evaluated. Only males evaluated. Unclear
mortality.
Fitzhugh
et al. (1950)
Rat (Wistar),
male/female
Duration: approximately 107 weeks
Sample Size: 10/sex/group; 20/sex/group
controls
Route: dietary, ad libitum
Dose Levels: 0, 10, 50, 100, 800 ppm
No gross tumors reported. Necrotic foci (<1 mm
diameter) and other degenerative changes
observed in highest dose (800 ppm) group.
Relative liver weight signiﬁcantly increased in
the 50, 100, and 800 ppm groups (dose-
dependent).
Rats exposed to 800 ppm had decreased body
weight gain and decreased survival compared
to controls; MTD exceeded.
Small sample size. Minimal details on
histopathology. High overall mortality in the
study. Inadequate discussion of mortality/
general toxicity. Data were not stratiﬁed by sex.
Gerlyng et al. (1994) Rat (Wistar), male Duration: 50 hours
Sample Size: 2-19/group
Route: oral gavage
Dose Levels: 0, 150 mg/kg
A single dose of HCH did not alter hepatocyte
ploidy. DNA labeling index (BrdU incorporation)
was maximal ~30 hours after a single HCH dose
and was increased in both mononuclear and
binuclear hepatocytes. DNA labeling was
signiﬁcantly increased in diploid, tetraploid,
and octaploid hepatocytes following daily 150
mg/kg oral doses of HCH; the proportion of
binuclear cells decreased, suggesting aberrant
proliferation.
Only males tested. Small sample size. Only one
dose level evaluated. The number of repeated
doses was not speciﬁed for the binucleation
experiment.
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Goto et al. (1972) Mouse (ICR-JCL),
male
Duration: 26 weeks
Sample Size: 10/group
Route: dietary (unknown if ad libitum)
Dose Levels: 600 ppm
Hepatoma (10/10) consisting of areas of atypical
proliferation, nodules, and tumors. Hepatoma
incidence in control animals not reported. No
ﬁbrosis. No metastases.
Relative liver weight was increased.
Only one dose level evaluated. Small sample
size. Only males tested. No statistical analysis.
Inadequate characterization of
histopathological changes. Mortality not
reported. Incidence of benign and malignant
tumors not reported. Inadequate translation
from German did not allow for comprehensive
review.
Hanada et al. (1973) Mouse (dd),
male/female
Duration: 32 weeks plus 5-6 weeks recovery
Sample Size: 10-11/sex/group; 20-21/sex/
group
controls
Route: dietary, ad libitum
Dose Levels: 0, 100, 300, 600 ppm
1/5 300 ppmmale, 1/4 300 ppm female, and 2/4
600 ppmmales had liver tumors at the week 26
laparotomy. Hepatoma observed after exposure
plus recovery: males 0/14, 1/8, 7/7, 7/7 and
females 0/15, 0/8, 2/3, 6/8.
Average tumor size increased with increasing
dose in exposure plus recovery group. No
microscopic peritoneal invasions or metastases
seen. Atypical proliferation in liver
(hypertrophic foci; associated with liver cell
damage) noted in all treated exposure plus
recovery mice except females at 100 ppm.
Incidence of 8/8 100 ppm males, 7/7 300 ppm
males, 3/3 300 ppm females, 7/7 600 ppm
males, and 8/8 600 ppm females. One 600 ppm
female had mammary carcinoma.
Small sample size. No statistical analysis.
Apparent increase in mortality in treated
animals that was not dose-dependent. General
toxicity data were not reported. No evaluation
done at the end of the 32week exposure period;
regression of changes could not be evaluated.
Ito et al. (1973a) Mouse (dd), male Duration: 24 weeks
Sample Size: 20-40/group
Route: dietary, ad libitum
Dose Levels: 0, 100, 250, 500 ppm
Dose-dependent increase in HCC (0/20, 0/20,
10/38, 17/20)
Dose-dependent increase in liver nodular
hyperplasia in treated mice (0/20, 30/38, and
20/20). No metastatic changes or tumors in
other organs were noted upon gross
examination. Dose-dependent increase in
relative liver weight. Severe liver cell
hypertrophy observed in 250 and 500 ppm
groups; less severe at 100 ppm. Necrotic or fatty
change rarely noted. Increased smooth
endoplasmic reticulum in carcinomas and non-
cancerous tissue. Body weight not affected.
Only males evaluated. No statistical evaluation.
Only examined liver histologically. Mortality
not reported.
Ito et al. (1973b) Mouse (dd),
male
Duration: 24 weeks
Sample Size: 26-30/group; 20/group controls
Route: dietary, ad libitum
Dose Levels: 0, 50, 100, 250 ppm
Nodule incidence of 23/30 and carcinoma
incidence of 8/30 in the 250 ppm group. No
nodules or carcinoma in 50 or 100 ppm groups.
Centrilobular hypertrophy observed in the 100
and 250 ppm groups (dose-dependent increase
in severity). No cirrhosis or metastases. Relative
liver weight was increased (dose-dependent).
Body weight not affected.
No statistical evaluation. Only males evaluated.
Unclear if extra-hepatic tumors/metastases
were evaluated microscopically. Mortality not
reported.
(continued on next page)
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Table 1 (continued )
Reference Species, Sex Study Design Summary of Findings Study Limitations
Ito et al. (1975) Rat (Wistar),
male
Duration: 72 weeks; interim sacriﬁces
Sample Size: 5-16/group
Route: dietary, ad libitum
Dose Levels: 0, 500, 1000, 1500 ppm
HCC observed only in 1000 and 1500 ppm
groups at 72 weeks (incidence of 1/16 and 3/13,
respectively).
Incidence of nodular hyperplasia as follows:
1000 ppm - 5/12 (48 weeks), 12/16 (72 weeks);
1500 ppm - 10/13 (72 weeks). None in control
or 500 ppm groups.
Increased relative liver weight in all dose
groups at all time points (dose-dependent).
Hepatic hypertrophy observed; dose- and time-
dependent increase in severity. Bile duct
proliferation and oval cells observed at 1000
and 1500 ppm (48 and 72 weeks only).
Control animals sacriﬁced at different time than
treated animals. Mortality not reported. Unclear
if metastases were evaluated grossly or
microscopically. Insufﬁcient description of
general toxicity. Only males evaluated. Small
sample size. No statistical evaluation.
Ito et al. (1976) Mouse (DDY),
male
Duration: 72 weeks; interim sacriﬁces and
recovery.
Sample Size: 12-20/group
Route: dietary, ad libitum
Dose Levels: 0, 500 ppm
Centrilobular hypertrophy observed after 16
weeks; regressed following cessation of
treatment. Incidence of liver tumors increased
progressively with continuous exposure (25%
after 16 weeks, 70% after 20 weeks, 100% after
24 weeks); some tumors regressed following
exposure cessation. Increased relative liver
weight over time; increases regressed following
exposure cessation. Metastases to regional
lymph nodes, lungs, or kidneys were not
observed microscopically.
After 24 weeks, most tumors were nodular
hyperplasia. At 60-72 weeks, most tumors were
HCC.
Increased amount of smooth endoplasmic
reticulumwas observed on electronmicroscopy
in the hyperplastic cells.
Only one dose level evaluated. Only males
evaluated. No statistical analysis. Apparent
increase in mortality over time and with longer
exposure.
Ito et al. (1983) Rat (Fisher 344),
sex not reported
Duration: Initiation with DEN and partial
hepatectomy followed by 6weeks of alpha-HCH
exposure. Some rats sacriﬁced at the end of the
6 weeks; other groups were periodically
sacriﬁced over a 50 week total duration.
Sample Size: 8-34/group for some endpoints;
not reported for other endpoints.
Route: dietary
Dose Levels: 0, 1000 ppm
No increase in number or area of hepatic
hyperplastic nodules, in number of degenerated
hyperplastic nodules, or in number of HCCs was
observed compared to control over the 50 week
experimental period. Hyperplastic nodule
number and area were signiﬁcantly increased in
DEN-initiated, partially hepatectomized rats
who received 6 weeks of dietary alpha-HCH and
were immediately sacriﬁced.
Lack ofmethodological details, including animal
sex and group size. Nomortality or toxicity data.
Kraus et al. (1981) Rat (Wistar),
male/female
Duration: 16 days; interim sacriﬁces
Sample Size: 5-10/group
Route: intraperitoneal or gavage
Dose Levels: 0, 3, 10, 30, 50, 100, 200 mg/kg
GST activity was signiﬁcantly increased 2, 4, and
6 days after a single intraperitoneal dose
(multiple GST substrates); GST was generally
not increased after a single oral dose, except for
6 days post-dose when an HCH metabolite was
used as the substrate. GST increases were
transient. GST activity increases were dose-
dependent and signiﬁcant at doses at or above
30 mg/kg (multiple substrates). Relative liver
weights were signiﬁcantly increased 2, 6, and
10 days after a single oral dose and 4 and 6 days
after a single intraperitoneal dose; increases
were transient in the intraperitoneal group.
GST activity and relative liver weights were
signiﬁcantly increased 6 days after a single ip
dose of 200 mg/kg in animals 14, 21, and 42
days old but not in 3 day old rats.
Only males evaluated. Small sample size.
Potentially irrelevant route of exposure
(intraperitoneal).
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Lee and Edwards (2001) Rat (Wistar),
male hepatocytes
Duration: 6 hours
Sample Size: 2 cultures
Route: in vitro
Dose Levels: 0, 30 microM
Prostaglandin E2 release was not increased in
treated hepatocytes.
Small sample size. Only one concentration
evaluated. Very little data presented on HCH,
including DNA synthesis data. Cell viability and
treatment cytotoxicity were not reported.
Luebeck et al. (1995) Rat (Wistar) female Duration: NNM initiation, 8 week recovery,
then 10 or 28 weeks alpha-HCH followed by 2,
6, or 21 week recovery
Sample Size: 3-7/group/time point
Route: dietary
Dose Levels: 0, 20 mg/kg bw
Volume fraction and mean number of hepatic
foci increased over an 18 or 36 week exposure
and decreased upon cessation of exposure.
No mortality or toxicity data. Only female rats
evaluated.
Masuda et al. (2001) Rat (F344), male Duration: 6 weeks after initiation by DEN and
partial hepatectomy
Sample Size: 15/group
Route: dietary, ad libitum
Dose Levels: 0, 0.01, 0.1, 0.5, 1, 2, 4, 7.5, 15, 30,
60, 125, and 500 ppm
GST-P-positive foci increased in dose-related
manner in groups receiving 0.5 ppm or more.
Numbers of GST-P positive foci signiﬁcantly
increased in groups treated with 2 ppm and
higher, with the exception of 4 ppm. Areas of
GST-P positive foci signiﬁcantly increased in
groups treated with 7.5 ppm and higher, with
the exception of 15 ppm.
Dose-dependent, signiﬁcant increases in CYP2B
protein from 60 ppm were seen. Testosterone
16B-hydroxylation activity was signiﬁcantly
increased in a dose-related manner from 30
ppm. CYP3A protein signiﬁcantly increased
(dose-dependent) from 4 ppm and testosterone
hydroxylation signiﬁcantly increased (dose-
dependent) from 15 ppm.
Relative liver weight signiﬁcantly increased in
the 7.5, 60, 125, and 500 ppm groups. Body
weight signiﬁcantly decreased in 15, 30, 60,
125, and 500 ppm groups.
The effect of HCH alone on foci formation was
not evaluated. Potential confounding effect of
partial hepatectomy. Only males evaluated.
Small sample size.
Nagasaki et al. (1975) Mouse (DDY), male;
Rat (Wistar), male;
Hamster (Golden
Syrian), male
Duration: 24 weeks
Sample Size: 20 rats, 16 hamsters, 36 mice; 48
mice in the second experiment
Route: dietary, ad libitum
Dose Level: 0, 500 ppm
Two experiments conducted (One for species
comparison, and one for comparison of alpha-
HCH +/- various other compounds).
Nodular hyperplasia (20/20 mice and 13/19
mice in ﬁrst and second experiments,
respectively) and HCC observed (6/20 mice and
8/19 mice in ﬁrst and second experiments,
respectively).
Centrilobular hypertrophy seen in all three
species; most pronounced in mice. No cirrhosis.
No tumors in rats or hamsters. Increased
relative liver weight in all three species; most
pronounced in mice. Reduced body weight gain
in rats and hamsters. Co-treatment with 3-MC
but not other enzyme inducers reduced the
incidence of mouse liver tumors.
Only one dose level evaluated. Only males
evaluated. Small sample size. No statistical
analysis. Only livers examined. Mortality not
reported. No evaluation of metastases.
(continued on next page)
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Table 1 (continued )
Reference Species, Sex Study Design Summary of Findings Study Limitations
Nagasaki et al. (1975) Mouse (DDY);
Mouse (CH3/He);
Mouse (DBA/2);
Mouse (ICR);
Mouse (C57BL/6),
male/female
Duration: 24 weeks
Sample Size: 13-29/sex/strain
Route: dietary, ad libitum
Dose Level: 0, 500 ppm
Strain comparison: Increased relative liver
weight in treated males and females of multiple
mouse strains; strain differences in the degree
of the increase. Centrilobular hypertrophy and
oval cells observed in males and females of
multiple mouse strains. Strain- and gender-
dependent differences in incidence of nodular
hyperplasia (16.7-100%) and HCC (0-65%). In
general, males were more susceptible than
females.
Only livers examined histologically. Only one
dose level evaluated. Mortality not reported. No
statistical analysis.
Puatanachokchai
et al. (2006)
Rat (F344), male Duration: 10 weeks following initiation with
DEN
Sample Size: 12/group
Route: dietary (unknown if ad libitum)
Dose Levels: 0, 0.01, 0.05, 0.1, 1, 50, 500 ppm
Dose-dependent increase in number and area of
GST-P positive foci (signiﬁcant at high doses);
foci number and area at 0.05 ppm were
signiﬁcantly decreased. The proportion of
proliferating cells (i.e., PCNA positive) within
GST-P positive foci decreased and then
increased (dose-dependent; signiﬁcant at
highest dose). Foci were observed in all treated
rats.
Total P450 content and P450 reductase activity
were signiﬁcantly decreased at 0.05 ppm but
signiﬁcantly increased at 500 ppm. P450
reductase protein level signiﬁcantly increased
at 50 and 500 ppm. Some signiﬁcant increases
in P450 activity at 50 and 500 ppm. Dose-
dependent increases in CYP2B, 2C, 2E, and 3A
protein levels; increases were signiﬁcant at 50
and 500 ppm.
Liver 8-OHdG levels signiﬁcantly decreased at
0.1 and 1 ppm but signiﬁcantly increased at 500
ppm. GST activity signiﬁcantly increased at 500
ppm.
Decreased body weight gain, signiﬁcantly
increased relative liver weight at 500 ppm.
Adenomas and HCCs observed only at 500 ppm
(mean of 2.8 tumors per rat).
Small sample size. Only males evaluated. The
effect of HCH alone, without initiation, was not
evaluated.
Schroter et al. (1987) Rat (Wistar), female Duration: 17 weeks (initiation); 15-20 weeks
following initiation by NNM (promotion)
Sample Size: 3-8/group (initiation study); 4/
group (promotion study)
Route: gavage or dietary, ad libitum
Dose Level: single oral bolus dose of 200 mg/kg
(initiation) or 0-20 mg/kg-day in the feed
(promotion)
Initiation Study: No increase in GGT-positive
foci in partially hepatectomized rats given a
single oral bolus dose followed by 15 weeks of
phenobarbital in the diet.
Promotion Study: Dose- and time-dependent
increases in foci number and area were
observed after 15 and 20 weeks. Foci area was
signiﬁcantly increased relative to control at
mid- to high-doses. Dose-dependent increases
in liver mass, liver DNA (both signiﬁcant at
highest dose tested), and P450 activities (not
signiﬁcant) were observed. P450 induction and
liver weight increases were not predictive of
foci formation. NOELs calculated.
Small sample size. Only females evaluated. Not
all data were statistically evaluated. Mortality
not reported. The effect of HCH alone, without
initiation, was not evaluated in the promotion
study.
Schulte-Hermann and
Parzefall (1980)
Rat (Wistar), female Duration: 6 days
Sample Size: 5-6/group
Route: oral gavage
Dose Levels: 0, 200 mg/kg
CYP1A, CYP2B, CYP2A, and CYP3A enzyme
activities were increased following a single oral
dose.
Only females evaluated. Small sample size. No
statistical analysis. Unclear if reaction
conditions were optimized.
A
.E.Bradley
et
al./
Regulatory
Toxicology
and
Pharm
acology
76
(2016)
152
e
173
160
Schulte-Hermann and
Parzefall (1981)
Rat (Wistar), female Duration: 24.5 months; interim sacriﬁces and
recovery.
Sample Size: 2-5/group
Route: oral gavage and/or dietary (unknown if
ad libitum)
Dose Levels: 0 and initial oral dose of 100mg/kg
followed by 18.4mg/kg-day in the diet; 420mg/
kg in 3 week intervals; or 200 mg/kg in 2 week
intervals.
Signiﬁcantly decreased body weight after 4.5
and 23.5 months of continuous exposure; also
decreased after 21.5 months of interval
exposure (n¼2). Signiﬁcantly increased relative
liver weight after 4.5, 13.5, or 23.5 months of
dietary exposure and after 11.5 months of
interval exposure; no clear temporal trend.
After 11.5 months of interval exposure followed
by recovery period, relative liver weights and
body weights were similar to control.
Signiﬁcantly increased RNA and DNA in liver
after continuous or interval treatment up to
23.5 months; no clear temporal trend. The
increases regressed in the 11.5 month interval
exposure plus recovery group.
Signiﬁcantly increased cytochrome P450
activity following 4.5, 13.5, and 23.5 months of
continuous or 11.5 months interval treatment;
no clear temporal trend. The increases
regressed in the 11.5 month interval exposure
plus recovery group.
Pronounced increase in GST activity after 11.5
months of interval treatment or 13.5 months of
continuous treatment.
Time-dependent increase in incidence of
macroscopic and microscopic liver lesions (foci,
nodules/tumors, and HCC). Low incidence of
HCC (1/6 and 1/8 continuous and interval-
treated rats after at least 20 months). High
incidence of liver nodules (5/6 and 6/8
continuous and interval-treated rats after at
least 20 months; 2/4 and 1/4 continuous and
interval-treated rats after at least 11.5 months;
3/8 interval-treated rats after 11 months).
Small sample size. Only females tested.
Inconsistent dosing regimen. High incidence of
microscopic foci in controls (3/9, 1/3, and 5/6).
Body weight decrease was severe (~20%) in the
21.5 month interval treatment and 23.5 month
continuous treatment groups. Mortality not
reported.
Schulte-Hermann
et al. (1981)
Rat (Wistar), female Duration: 8 weeks after DEN; interim sacriﬁce
Sample Size: 5-6 rats/group
Route: oral gavage
Dose Levels: 0, 150-200 mg/kg each +/- DEN
initiation
After 2 HCH doses at 5 and 8 weeks after DEN
initiation, the proportion of GGT-positive foci of
larger size increased signiﬁcantly.
DNA synthesis in GGT positive and normal cells
was signiﬁcantly increased in HCH-treated
animals relative to the same cell type in control
animals. Among HCH-treated animals initiated
with either DEN or NNM, DNA synthesis was
signiﬁcantly higher in GGT positive cells
compared to normal cells.
For one experiment, DEN was given for 40 days
followed 25 days later by a single 200 mg/kg
oral bolus dose of HCH. DNA synthesis in GGT
positive cells was greater than in normal
hepatocytes. DNA labeling was not different in
GGT positive islands of different sizes (40 days
of DEN followed 25 days later by 200 mg/kg
HCH). Mitotic index was increased in DEN
initiated rats given a single 200 mg/kg dose of
HCH 3 or 11 months later. No GGT-positive
islands were found in rats treated with HCH
alone.
Small sample size. Only females evaluated.
Inconsistent dosing regimen. Potential
confounding effect of initiator administration.
(continued on next page)
A
.E.Bradley
et
al./
Regulatory
Toxicology
and
Pharm
acology
76
(2016)
152
e
173
161
Table 1 (continued )
Reference Species, Sex Study Design Summary of Findings Study Limitations
Schulte-Hermann
et al. (1983)
Rat (Wistar), female Duration: unclear (gavage study); 28 weeks
(dietary study)
Sample Size: not speciﬁed
Route: oral gavage or dietary, ad libitum
Dose Level: 0, 200 mg/kg (gavage); 0, 20 mg/kg
(dietary)
DNA synthesis and mitotic index were
increased in GGT-positive liver cells in initiated
rats after a single oral dose of HCH.
Mean GGT-positive island size increased after
28 weeks of dietary HCH exposure in NNM-
initiated rats relative to NNM treatment alone.
Sample size not reported. Unclear duration. No
statistical analysis. Only females evaluated. The
effect of HCH alone on island formation was not
evaluated.
Siglin et al. (1991) Mouse (B6C3F1),
male/female
Duration: 14 days or 28 weeks (separate
experiments)
Sample Size: 15/sex/group
Route: dietary, ad libitum
Dose Levels: 0, 250 ppm each +/- DEN initiation
No foci or adenomas observed in HCH-only or
control mice after 28 weeks. Very high number
of adenomas in DEN-initiated male mice (no
HCH); number signiﬁcantly decreased after 24
weeks of HCH exposure. In females, adenoma
number in DEN-only mice was very low and
signiﬁcantly increased after 24 weeks of HCH.
Adenoma number overall was higher in male
mice. Progressively increasing DNA labeling
was seen over 14 days of dietary exposure
(signiﬁcant at 7 and 14 days) in foci and
surrounding tissue in non-initiated males and
females and in DEN-initiated females. DNA
labeling was signiﬁcantly decreased after 14
days in DEN-initiated males.
Only one dose level evaluated. Small sample
size. Only liver examined. No body weight or
mortality data reported. DNA labeling data were
not differentiated according to cell type (i.e., foci
vs. normal hepatocytes).
Questionable relevance of initiation due to
differentially high adenoma incidence in DEN-
only males.
Siglin et al. (1995) Mouse (B6C3F1), male/female Duration: 14 days or 28 weeks (separate
experiments)
Sample Size: 15/sex (promotion study); 10/sex
(DNA synthesis study)
Route: dietary, ad libitum
Dose Levels: 0, 250 ppm each +/- DEN initiation
Signiﬁcantly increased relative liver weight in
males and females initiated with DEN and
exposed to HCH for 24 weeks; no increase after
HCH-only treatment. Signiﬁcantly decreased
body weight in HCH-only and DEN+HCH males.
Foci incidence of 4/15 males and 1/15 females
receiving HCH only for 24 weeks (no initiation).
Foci incidence 100% in males and females
treated with DEN only. Hepatocellular adenoma
incidence of 4/15 HCH-only males, 15/15 DEN-
only and DEN+HCH males, 0/15 HCH-only
females, 1/15 DEN-only females, and 11/15
DEN+HCH females (signiﬁcant increase) after 28
weeks. DNA labeling after 14 days was
signiﬁcantly increased in normal liver from
DEN+HCH males and females compared to DEN
only, but not in foci. DNA labeling in general
was higher in foci.
Only liver examined. Only one dose level
evaluated. Small sample size. Only liver
examined. Differential susceptibility of infant
male mice to DEN-mediated adenoma
formation. Questionable relevance of initiation
due to high incidence of foci in DEN-only
animals and high incidence of adenoma in DEN-
only males.
Sumida et al. (2007) Rat (F344), male Duration: 28 days; interim sacriﬁces
Sample Size: 4/group
Route: oral gavage
Dose Levels: 0, 2, 20 mg/kg-day
Hepatocellular hypertrophy seen in high-dose
animals (0/4, 0/4, 4/4) .
Signiﬁcantly increased relative liver weight
after 3 days at 20 mg/kg-day; no consistent
signiﬁcant increases in the 2 mg/kg-day group
were seen. Dose-response evident but no clear
temporal trend.
Progressive and signiﬁcant (except day 3) time-
dependent decrease in ALP in 20 mg/kg-day
animals beginning 1 day post-dose.
Increased GST and P450 isoform expression was
seen at the 28 day time point. Some increases
also noted at 1 and 3 days, but there was no
clear temporal trend.
Only males evaluated. Small dose groups.
Results not conﬁrmed with PCR. Inconsistency
in most changes over time.
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Thamavit et al. (1974) Rat (Fisher), male Duration: 6 months; 2 month interim sacriﬁce
and 5month exposure plus onemonth recovery
Sample Size: 3-6/group
Route: dietary, ad libitum
Dose Level: 0, 0.06% (600 ppm)
No abnormal histology, nodules, or carcinoma
at 2 months or 6 months.
Moderate increase in relative liver weight at 2
months; very slight increase at 6 months.
Decreased body weight gain after 6 months; no
change after 2 months.
Small sample size. Only males evaluated. Only
one dose level evaluated. No statistical
evaluation. Only evaluated the liver. Mortality
not reported. Animals not sacriﬁced at 5months
to assess the effect of the 1 month recovery
period.
Tryphonas and
Iverson (1983)
Mouse (HPB), male Duration: 50 weeks; interim sacriﬁces
Sample Size: 75 -treatment group; 48 -control
group; 4-9/group interim sacriﬁces
Route: dietary, ad libitum
Dose Levels: 0, 500 ppm
Gross (29% incidence) and microscopic (57%
incidence) nodules of the liver observed
beginning at 21 weeks of exposure; incidence
was 100% at 33 weeks. All nodules were benign
(adenoma).
No gross evidence of metastases in the lungs.
Increased relative liver weight (time-
dependent) and megalocytosis observed in
exposed mice. Increased mitotic index in
megalocytic and nodular hepatocytes. Single
cell necrosis, lipid accumulation, and nodules
arising from areas of megalocytic cells were
observedmicroscopically. Reduced bodyweight
gain in treated mice after 50 weeks.
Only one dose level evaluated. Small sample
size. Only males tested. No statistical analysis.
Only examined the liver and lungs. Emaciation
noted in mice with severe liver enlargement or
large tumors. Initial body weights not reported.
Tsukada et al. (1979) Mouse (DD), male Duration: 36 weeks; interim sacriﬁces
Sample Size: 6/group
Route: dietary, ad libitum
Dose Levels: 0, 500 ppm
Centrilobular hypertrophy observed beginning
at 16 weeks. Periportal atrophy observed.
Hyperplastic nodules: 1/6 mice at 16 weeks; 5/6
mice at 20weeks. 2/6mice had hepatomas at 28
weeks; 3/6 mice had hepatomas at 32-36
weeks.
Proliferation of smooth endoplasmic reticulum
was noted; peroxisome proliferation was not
observed at 16-20 weeks.
Only one dose level evaluated. Small sample
size. Only males evaluated. Mortality and body
weights not reported. Background tumor
incidence could not be evaluated in control
mice (due to short duration of inclusion in the
study).
Werle-Schneider
et al. (2006)
Rat (Wistar), male
liver slices
Duration: 24 hours
Sample Size: 8 liver slices from 4 rats
Route: in vitro
Dose Levels: 0, 0.1, 1, 10, 100 microM
Some dose-dependent changes in expression
are suggested (e.g., ubiquitin, P-glycoprotein,
GAPDH, retinoblastoma, p53, UGT isoforms,
ERK, GST isoforms, P450 isoforms).
Results not conﬁrmed by PCR. Inconsistency of
most changes over time.
Notes:
8-OHdG ¼ 8-hydroxy deoxyguanosine
ALP ¼ alkaline phosphatase
BrdU ¼ bromo-deoxyuridine
CYP ¼ cytochrome P450
DEN ¼ diethylnitrosamine
ERK ¼ extracellular signal-regulated kinase
GAPDH ¼ glyceraldehyde phosphate dehydrogenase
GGT ¼ gamma-glutamyl transpeptidase
GST ¼ glutathione-S-transferase
GST-P ¼ glutathione-S-transferase, pi isoform
HCC ¼ hepatocellular carcinoma
MTD ¼ maximum tolerated dose
NNM ¼ N-nitrosomorpholine
NOEL ¼ no-observed-effect level
P450 ¼ cytochrome P450
PCNA ¼ proliferating cell nuclear antigen
SOD ¼ superoxide dismutase
TBARS ¼ thiobarbituric acid reactive substance
UGT ¼ UDP-glucuronosyl transferase
A
.E.Bradley
et
al./
Regulatory
Toxicology
and
Pharm
acology
76
(2016)
152
e
173
163
Table 2
Evaluation of the hypothesized MOA using EPA's causation criteria.
Criteria Evaluation Findings
Strength, Speciﬁcity, and
Consistency of the Association
- P450-related parameters such as isozyme protein and activity, total P450, and P450 reductase were consistently increased in
independent studies of varying experimental design. Statistically signiﬁcant increases in total P450 and P450 reductase
activity and/or protein were seen in 2/2 studies which examined these effects. Statistically signiﬁcant increases in P450
isozyme activity were seen in 3/4 studies which examined this effect; in the fourth study, increased P450 was also seen but
these data were not statistically evaluated. This trend is supported by two microarray studies which found increased P450
isozyme expression; themicroarray data themselves were not conclusive. The small sample size in some studies is a limitation
to evaluating the role of P450 induction.
- Increased cell growth and proliferation have been consistently observed in numerous independent studies of
varying experimental design. Markers of cell growth (e.g., relative liver weight, hypertrophy, foci formation, DNA
labeling) were increased in almost every study in which these endpoints were examined. These effects occurred at
high incidence or were statistically signiﬁcant in most cases. Only two studies did not show a signiﬁcant increase in
markers of cell proliferation; the lack of an effect may be due to short study duration or species/strain differences in
response.
Dose-Response Concordance - Consistent dose-dependent increases in markers of P450 parameters and cell proliferation were observed in each
study in which multiple dose levels/concentrations were evaluated. A consistent observation across endpoints
was that of no increase at low doses, suggesting a threshold, and, in some cases, hormesis. A lack of dose-response
was observed in one study where the incidence of response was 100% at all doses, which illustrates the potency of
the doses used.
Temporal Association - Temporal relationships between exposure and P450 parameters and increased cell proliferation were consistently seen across
studies. Two types of temporal patterns were observed: increased response over time and regression of response following
cessation of exposure. None of the studies evaluated was inconsistent with a temporal pattern. Regression of increases in P450
activity, liver DNA/RNA content, liver weight, and hypertrophy were seen in several studies following cessation of exposure,
which further supports the role of alpha-HCH as a tumor promoter.
Biological Plausibility
and Coherence
- The reported MOA is consistent with what is known about carcinogenesis. The roles of P450 induction and
increased cell proliferation in carcinogenesis are well established. Other chemicals have been shown to elicit
similar effects via induction of P450 and increased cell proliferation. The database for alpha-HCH is internally
consistent in supporting the reported MOA.
A.E. Bradley et al. / Regulatory Toxicology and Pharmacology 76 (2016) 152e173164Increases in total P450, P450 isoform protein/activity, and P450
reductase activity have been observed in parallel with increased
proliferation or increased liver weight, and hepatic foci formation
(Barros et al., 1991; Masuda et al., 2001; Puatanachokchai et al.,
2006; Sumida et al., 2007).3.1.1.3. Key event 3 e cellular proliferation. Exposure to alpha-HCH
results in increased hepatocellular proliferation, as evidenced by
increased liver DNA synthesis, hypertrophy, and hyperplasia,
leading to increased relative liverweight in both rats andmice. DNA
synthesis is increased in hyperplastic and, in some cases, normal
liver tissue from exposed mice (Gerlyng et al., 1994; Schulte-
Hermann et al., 1981; Siglin et al., 1991, 1995; Tryphonas and Iver-
son, 1983) and is observed after single oral doses or long-term di-
etary exposure to alpha-HCH (Schroter et al., 1987; Schulte-
Hermann et al., 1981, 1983).
The observed increase in DNA synthesis occurs in hepatocytes of
differing chromosomal content; however, the proportion of binu-
clear hepatocytes decreases during mitogenesis (Gerlyng et al.,
1994). Decreased binucleation is indicative of loss of terminal dif-
ferentiation and entrance into an aberrant pattern of cell growth
(Guidotti et al., 2003).
Following long-term alpha-HCH exposure, observed in-
creases in hypertrophy, gamma-glutamyl transpeptidase (GGT)
positive foci formation, DNA content, and liver weight are dose-
dependent (Fitzhugh et al., 1950; Goto et al., 1972; Ito et al.,
1973a,b; Luebeck et al., 1995; Masuda et al., 2001; Schroter
et al., 1987). Alpha-HCHemediated increases in centrilobular
hyperplasia or hypertrophy, liver DNA and RNA content, andliver weight regress after cessation of exposure (Angsubhakorn
et al., 1981; Ito et al., 1976; Kraus et al., 1981; Schulte-Hermann
and Parzefall, 1981), further supporting the tumor-promoting
effect of the chemical.
3.1.1.4. Key event 4 e benign and malignant tumor formation.
Chronic administration of high doses of alpha-HCH has been
shown to produce both benign and malignant tumors in mice and
rats (Hanada et al., 1973; Ito et al., 1973a,b; Ito et al., 1975; Ito et al.
1976; Nagasaki et al., 1975; Schulte-Hermann and Parzefall, 1981;
Tryphonas and Iverson, 1983), with increased sensitivity for mice
(Nagasaki et al., 1975). Tumor formation exhibits a threshold
response. For example, Ito et al. (1973a,b) observed increases in
carcinomas in the livers of mice dosed with greater than or equal
to 250 ppm alpha-HCH, but no increase in the livers of animals
dosed with 50 and 100 ppm alpha-HCH. Ito et al. (1975) observed
carcinomas in the liver of rats dosed with 1000 and 1500 ppm
alpha-HCH, but no increase in rats dosed with 500 ppm alpha-
HCH.
3.1.1.5. Alternative MOAs. From a human risk perspective, the most
crucial potential alternative MOA for alpha-HCH is mutagenicity.
Although some evidence of genotoxicity has been observed, the
lack of a consistent positive response in the short-term bioassays
conducted in a variety of in vitro and in vivo systems, evaluating a
Table 3
Summary of mutagenic assays for Alpha-HCH.
Reference In Vitro/In Vivo Species/Strain/Cell Type Assay/Test Treatment Result Comments
Mutation
Moriya et al. (1983) In vitro Salmonella typhimurium TA98, TA100,
TA1535, TA1537, TA1538
Ames assay up to 5,000 mg/plate
w/ and w/out activation
Negative
Escherichia coli WP2 Reverse mutation assay up to 5,000 mg/plate
w/ and w/out activation
Negative
Shahin and von
Borstel (1977)
In vitro Saccharomyces cerevisiae
XV185-14C
Reverse mutation assay 0.1e200 mg/ml
w/ and w/out activation
Negative
Tanooka (1977) In vitro Bacillus subtilis TKJ5211 Spot test 5,000 mg/plate Negative
DNA Binding
Iverson et al. (1984) In vitro Calf (thymus DNA) e 1 mm Weakly positive Low levels of DNA binding only consistent with
a non-genotoxic mechanism for neoplastic
response.
In vivo Mouse liver e 25 mg/kg Weakly positive Low levels of DNA binding only consistent with
a non-genotoxic mechanism for neoplastic
response.
Sagelsdorff et al. (1983) In vivo NMRI mouse liver HPLC analysis of nucleosides 6.2e8.5 mg/kg Weakly positive “Minute DNA binding”. Binding is more than
three orders of magnitude lower than would be
expected if the mechanism of tumor induction
was genotoxicity mediated by DNA binding.
DNA Damage, Fragmentation, and Repair
Kalantzi et al. (2004) In vitro Human MCF-7 breast carcinoma cells Comet assay 10e4 M Positive At lower concentrations no comet-forming
effects were observed.
Human PC-3 prostate carcinoma cells Comet assay 10e4 M Positive At lower concentrations no comet-forming
effects were observed.
Mattioli et al. (1996) In vitro Human hepatocytes Comet assay 0.056e0.32 mM Positive
Rat hepatocytes Comet assay 0.056e0.32 mM Positive Modest, dose-dependent increase in DNA
breaks.
Mouse hepatocytes Comet assay 0.056e0.32 mM Negative
Venkat et al. (1995) In vitro Escherichia coli PQ37 SOS microplate assay NA See comment Results provide a relative scale of activity.
Alpha-HCH had levels of activity that ranged
1/10 to 1/4 (dependent on dosing vehicle) that
of 4-NQO, which is considered to be a direct
acting mutagen.
Hitachi et al. (1975) In vivo Liver cells from Donryu rats Chromosomal alterations e Inspection
for cell distribution e % by ploidy
600 ppm Positive
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the notion that alpha-HCH is mutagenic. Table 3 presents a sum-
mary of the available short-term bioassays for mutagenic potential
of alpha-HCH.
Results of four in vitro assays testing for gene mutation at a
variety of concentrations, both with and without metabolic
activation, were negative. Alpha-HCH has shown the ability to
bind to DNA in both in vitro and in vivo test systems, however
the levels of DNA binding were weak (Iverson et al., 1984;
Sagelsdorff et al., 1983). Sagelsdorff et al. (1983) characterize
it as “minute DNA binding,” stating that “the level of binding is
more than three orders of magnitude lower than would be
expected if the mechanism of tumor induction was genotox-
icity.” Several assays measuring DNA damage or fragmentation,
or repair of such damage, showed mixed results. Kalantzi et al.
(2004) report positive results for a comet assay for DNA frag-
mentation performed with high doses of alpha-HCH but note
that at lower concentrations, no comet-forming effects were
observed (data not shown by authors). Mattioli et al. (1996)
found alpha-HCHeinduced, dose-dependent strand breaks
in vitro in rat and human hepatocytes; however, no DNA strand
breaks were observed in mouse hepatocytes. DNA synthesis,
indicative of lesion repair or general proliferation, was not
increased in rat or human hepatocytes despite observed DNA
fragmentation, which suggests that any induced damage was
not sufﬁcient to elicit a detectable repair response (Mattioli
et al., 1996). Venkat et al. (1995) provide results on a relative
scale of activity for the induction of gene pathways involved in
DNA repair. The study reports that alpha-HCH showed activity
levels ranging from one-tenth to one-fourth of 4-Nitro-quino-
line oxide (4-NQO), which is considered a direct-acting
mutagen. The single study we reviewed for chromosomal ab-
normalities reports positive results in liver cells from Donryu
rats given a single dose of 600 ppm in vivo (Hitachi et al.,
1975).
Liver tumors can be induced in rodents by cytotoxic agents;
however, examination of the literature reveals that induced tumors
in rats and mice are observed at dose levels that are not associated
with any evidence of marked hepatotoxicity.
3.1.2. Human relevance
In deriving a cancer slope factor (CSF) for alpha-HCHeinduced
liver cancer, EPA assumes that alpha-HCH is a probable human
carcinogen (i.e., classiﬁcation B2). Given EPA's current assump-
tion, the animal cancer response and MOA were assumed to be
relevant for humans for the purposes of this dose-response eval-
uation, including the derivation of a toxicity criterion for the
protection of public health. As such, we developed a threshold-
based RfD for the protection of alpha-HCHeinduced cancer. The
current state of knowledge regarding the human relevance of the
deﬁned MOA for alpha-HCH hepatocarcinogenicity is presented
below.
Activation of nuclear receptors and subsequent induction of
P450 is a well-known MOA for rodent hepatocarcinogenesis.
Activation of CAR, PXR, and PPAR-alpha produces a cascade of
alternations in gene transcription that leads to increasedhepatocellular proliferation, a critical event in the develop-
ment of liver tumors (Elcombe et al., 2014; Klaunig et al.,
2003; Cohen, 2010; Williams and Iatropoulos, 2002; Hall
et al., 2012).
Compound-speciﬁc evidence regarding the human relevance
of this MOA for alpha-HCHeinduced hepatocarcinogenesis is
sparse; however, information from other well studied com-
pounds informs the human relevance evaluation for alpha-HCH.
For example, phenobarbital (PB) is a well studied liver carcin-
ogen that operates via a receptor-mediated mechanism that al-
ters gene transcription, leading to increased cellular
proliferation and eventually to the development of liver tumors
(Whysner et al., 1996); similarities in the toxic activity of alpha-
HCH and PB toward the liver have been observed in Schroter
et al. (1987), Schulte-Hermann et al. (1981, 1983), Werle-
Schneider et al. (2006), and Fukushima et al. (2005). Key
events for PB-induced liver carcinogenesis in rodents have been
described by Elcombe et al. (2014) to include (1) activation of
CAR, (2) altered gene expression speciﬁc to CAR activation, (3)
increased cell proliferation, (4) clonal expansion leading to
altered foci, and (4) formation of liver adenomas/carcinomas.
Exposure to PB in humans likewise leads to activation of CAR
and PXR and to the induction of P450; however, a different
pattern of response is induced in humans compared to rodents
(reviewed in Elcombe et al., 2014; Lake, 2009). Following
exposure to PB, no evidence of increased hepatocellular prolif-
eration in humans or in primary human hepatocytes in vitro
exists (Elcombe et al., 2014; Lake, 2009; Parzefall et al., 1991). A
single in vitro study also reports that alpha-HCH does not induce
hepatocellular proliferation in human hepatocytes (Parzefall
et al., 1991). Experiments with transgenic mice, in which
mouse receptors have been replaced with their human coun-
terparts, have shown conﬂicting results. Elcombe et al. (2014)
provide a summary of two such studies. In the ﬁrst, wild-type
mice treated with PB-induced P450 enzymes produced hepato-
cellular hypertrophy, increased DNA synthesis, and increased
liver weight, whereas humanized mice, in which the CAR/PXR
receptors were replaced with hCAR/hPXR induced P450 en-
zymes and produced hepatocellular hypertrophy but did not
increase replicative DNA synthesis. In the second study, treat-
ment of hCAR mice with PB resulted in increases in P450 mRNA
levels, relative liver weight, and cell proliferation. Elcombe et al.
(2014) hypothesize that the difference in results may be
explained by differences in the models developed or in the
treatment regimens for the two studies; however, ﬁrm conclu-
sions regarding the human relevance of the receptor-mediated
pathway for PB -induced liver carcinogenesis cannot be drawn.
There is no evidence of liver cancer in humans following phar-
maceutical administration of PB (as summarized by Elcombe
et al., 2014).
Beyond alpha-HCHe and PB- speciﬁc information, experts have
opined, more generally, on what constitutes a relevant adverse
effect in the context of hepatocellular hypertrophy. An expert panel
convened by the European Society of Toxicologic Pathology (ESTP)
concluded that observations in chemically exposed laboratory ro-
dents of increased liver weight, hepatocellular hypertrophy, and
cell proliferation in the absence of overt hepatotoxicity and medi-
ated via CAR, PXR, or PPAR-alpha should be considered a “non-
A.E. Bradley et al. / Regulatory Toxicology and Pharmacology 76 (2016) 152e173 167adverse” effect for human exposures (Hall et al., 2012). Under these
conditions, hepatocellular changes are considered to be fully
reversible and do not compromise viability or functional integrity
(Hall et al., 2012).
3.2. Dose-response analysis and toxicity criterion development
Increased incidence of liver adenomas and carcinomas have
been observed at relatively high doses above 150 ppm (Ito et al.,
1973a,b, 1975, 1976; Hanada et al., 1973; Nagasaki et al., 1975;
Schulte-Hermann and Parzefall, 1981). The lowest administered
doses for which tumor incidence was observed are equivalent to
average daily doses on the order of 45 mg/kg-day (Ito et al.,
1973a,b) and an initial dose of 100 mg/kg followed by 18.4 mg/
kg-day for approximately 13.5 months (Schulte-Hermann and
Parzefall, 1981). Lower-dose studies, many of which were
designed to measure the progression of and/or mechanisms
responsible for alpha-HCH toxicity, demonstrate that known or
hypothesized precursors to hepatocarcinogenicity or hepatotox-
icity occur at lower doses. Our evaluation focused on low-dose
studies, deﬁned here as studies with at least one animal treat-
ment dose of 10 mg/kg-day or less.
Endpoints considered for the POD included increased liver
weight (absolute and relative measures), increased DNA content,
and increased number or area of preneoplastic foci. Each of these
endpoints potentially reﬂects the occurrence of key events associ-
ated with alpha-HCH hepatocarcinogenicity and may be thought of
as precursors to alpha-HCHeinduced hepatocarcinogenicity.
Nonspeciﬁc, early markers of exposure, including P450 levels and
activity, were not considered as endpoints in the POD
determination.
Table 4 summarizes the ﬁndings of the BMD modeling. The
lowest statistically signiﬁcant NOAEL that was appropriate for the
POD determination from each study was also considered. For
studies for which no NOAEL was available, a LOAEL was selected.
Table 5 summarizes the available NOAELHEDs and LOAELHEDs
considered in determining the POD.
3.2.1. BMD modeling results
Four studies (Puatanochokchai et al., 2006; Schroter et al.,
1987; Masuda et al., 2001; and Sumida et al., 2007) contained
endpoints that were suitable for BMD modeling. All selected
endpoints had at least one model that provided an adequate ﬁt
to the data, and the BMDLHEDs from the best-ﬁt models selected
for each modeled endpoint ranged from 0.049 to 2.2 mg/kg-day.
BMDLHEDs associated with foci formation (increased number of
foci, and increased area of foci) fell in the lower end of this range
(0.049e0.072 mg/kg-day), while those for DNA content and liver
weight fell in the higher end of the range (0.22e2.2 mg/kg-day)
(Table 4).
3.2.2. NOAELs/LOAELs
Fitzhugh et al. (1950) established a LOAEL of 3.7 mg/kg-day
and a NOAEL of 0.74 mg/kg-day, equivalent to a NOAELHED of0.20 mg/kg-day, in males for slight microscopic changes and
increased liver weight. A slightly higher effect level was
measured in female rats (LOAEL of 4.2 mg/kg-day and a NOAEL of
0.84 mg/kg-day). The NOAEL of 0.74 mg/kg-day provided the
basis for one of the two RfDs derived by EPA in the 2006 eval-
uation of other HCH isomers, which was completed as part of the
reregistration eligibility decision (RED) for Lindane (USEPA,
2006). Sumida et al. (2007) established a slightly lower LOAEL
of 2 mg/kg-day (equivalent to a LOAELHED of 0.38 mg/kg-day) for
increased relative liver weight and alanine aminotransferase
(ALT) following 28 days of exposure to alpha-HCH in male rats.
The LOAEL was observed at the lowest dose tested, and no
NOAEL was established for these endpoints.
Masuda et al. (2001), Puatanachokchai et al. (2006), and
Schroter et al. (1987) established LOAELs for changes in foci
formation (i.e., number and area of hepatic foci) in rats. In all
three studies, animals were dosed with alpha-HCH after expo-
sure to a known initiator, and then changes were measured after
subchronic or nearly subchronic exposures. Although the study
designs are variable, there is an observable consistency in the
LOAELHEDs identiﬁed across the three studies measuring foci
formation, with values ranging from 0.75 to 2.8 mg/kg-day,
equivalent to LOAELHEDs from 0.21 to 0.70 mg/kg-day. The range
of NOAELHEDs associated with these effects is 0.014e0.12 mg/kg-
day.3.2.3. Synthesis
The BMDmodeling results and NOAELs/LOAELs were considered
for selecting the POD for alpha-HCH. The collective results
demonstrate that endpoints, including the incidence of hepatic foci
and foci area, were themost sensitive, while changes in liver weight
and DNA content were less sensitive. All of the effects measured in
the low-dose range were signiﬁcantly lower than dose levels at
which tumor formation was observed. Effect levels associated with
foci formation were therefore considered to be conservatively
appropriate for the basis of a POD.
BMD modeling established a range of BMDLHEDs of
0.049e0.072 mg/kg-day for increased foci area and number, based
on ﬁndings from Schroter et al. (1987) and Parzefall (2010). Three
studies reported NOAELs for these effects. The lowest NOAELHED
from the three studies that measured an endpoint for foci devel-
opment was 0.014 mg/kg-day (Puatanachokchai et al., 2006);
however, as evidenced by a comparison of LOAELs across the three
studies (Puatanachokchai et al., 2006; Masuda et al., 2001; Schroter
et al., 1987) (Table 5), the signiﬁcantly lower NOAELHED from Pua-
tanachokchai is likely an effect of the large intervals in the low end
of the dosing regimen. The NOAELHEDs from Masuda et al. (2001)
and Schroter et al. (1987) were an order of magnitude higher, at
0.11 and 0.12 mg/kg-day, respectively.
Data from Masuda et al. (2001) and Puatanachokchai et al.
(2006) for foci number and area were not suitable for BMD
modeling because these data were presented only in graphical
format. Given the recognized advantages that the BMD method
holds over the use of NOAELs and LOAELs in establishing PODs
(USEPA, 2012), preference was given to the BMDLHEDs established
from Schroter et al. (1987), i.e., 0.049 and 0.072 mg/kg-day for in-
creases in foci area and foci number, respectively (Table 4; Figs. 1
and 2). Based on the average of these two results, the HED POD
determined for alpha-HCH is 0.061 mg/kg-day.
Table 4
BMD modeling results for critical effects.
Study Endpoint/Critical Effect Benchmark Response Factor Model BMDHED (mg/kg-day) BMDLHED (mg/kg-day) AIC p-valuea Scaled residualb
Schroter et al. 1987 Foci number 1 SD Polynomial (third order) 0.15 0.072 82 0.28 0.12
Power 0.39 0.26 83 0.13 1.3
Schroter et al. 1987 Foci area 1 SD Exponential e Model 4 0.16 0.11 77 0.15 0.09
Polynomial (second order) 0.2 0.1 77 0.17 0.13
Polynomial (third order) 0.096 0.049 ¡79 0.47 ¡0.31
Power 0.17 0.11 77 0.15 0.11
Schroter et al. 1987 DNA content 1 SD Exponential e Model 2 2.5 1.6 23 0.8 ¡0.57
Exponential e Model 3 3.6 1.7 24 0.82 0.0012
Exponential e Model 4 2.4 1.5 25 0.46 0.63
Polynomial (second order) 3.5 1.1 24 0.82 0.0068
Power 3.6 1.5 24 0.82 0.0012
Masuda et al. 2001 Relative liver weight 10% relative change Exponential e Model 2 2.4 2.2 ¡130 0.26 ¡0.82
Polynomial (second order) 2.3 1.8 130 0.14 0.85
Power 2.4 1.7 130 0.12 0.77
Sumida et al. 2007 Relative liver weight 10% relative change Exponential e Model 2 1.7 1.5 33 0.12 1.1
Day 28 Power 1.6 1.4 ¡34 0.15 1.1
Sumida et al. 2007 Absolute liver weight 10% relative change Exponential e Model 2 2.3 1.7 2.1 0.66 0.023
Day 28 Power 2.2 0.22 ¡2.1 0.68 ¡0.025
Puatanachokchai et al. 2006 Relative liver weight 10% relative change Polynomial (third order) 0.72 0.71 ¡140 0.45 0.082
Puatanachokchai et al. 2006 Absolute liver weight 10% relative change Polynomial (third order) 0.72 0.71 67 0.71 0.000038
Notes:
The selected model for each study and endpoint is shown in bold text.
a Goodness-of-ﬁt test, p-value  0.1 is deemed a good ﬁt to the data.
b Scaled residual near the range of the BMD.
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Table 5
Summary of NOAELs and LOAELs for critical effects.
Study Endpoint/Critical Effect LOAELHED (mg/kg-day) NOAELHED (mg/kg-day)
Fitzhugh et al. (1950) Slight microscopic changes and increased liver weight Males e 1.0; Females e 1.0 Males e 0.20; Females e 0.21
Masuda et al. (2001) Increased number of GST-P positive foci 0.21a 0.11
Puatanachokchai et al. (2006) Increased number of GST-P positive foci 0.70 0.014
Sumida et al. (2007) Increased relative liver weight and increased liver ALT 0.38 e
Schroter et al. (1987) Increased area of foci 0.49 0.12
a Masuda et al. reports an increase in the number of GST-P positive foci at 0.2 mg/kg-day; however, the effect dropped off at the next highest dose tested and only began to
display a positive dose-response relationship at 0.75 mg/kg-day equivalent to a LOAELHED of 0.21 mg/kg-day.
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The following UFs were applied to the POD in determining the
cancer-based RfD for alpha-HCH:
 Intraspecies Extrapolation Factor e A default value of 10 was
selected for this factor to account for the variation in sensitivity
among members of the human population. The default value
was selected in the absence of any data on the toxicity of alpha-
HCH in humans.
 Interspecies Extrapolation Factor e A value of 3 was selected
for this factor. One standard approach is to apply an UF of 10 0
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Fig. 1. BMDS Polynomial (3rd Order) Model Results for Foci Area. Model results for foci area
lower conﬁdence limit for the BMDL. BMD ¼ benchmark dose, BMDL ¼ benchmark dose loto account for toxicokinetic and toxicodynamic differences in
the equivalent dose between animals and humans. However,
the allometric scaling recommended in EPA's cancer guide-
lines (USEPA, 2005) and employed in the estimation of the
POD accounts for differences in toxicokinetics between
humans and animals and also for some toxicodynamic vari-
ability (USEPA, 2006). In situations where such allometric
adjustments are employed, EPA recommends that an UF of 3
be applied to the allometrically scaled dose to account for
toxicodynamic differences between animals and humans
(USEPA, 2005, 2006). 3  4  5
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based on Schroter et al. 1987 using a BMR of 1 standard deviation for the BMD and 95%
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Fig. 2. BMDS Polynomial (3rd Order) Model Results for Foci Number. Model results for foci number are based on Schroter et al. 1987 using a BMR of 1 standard deviation for the
BMD and 95% lower conﬁdence limit for the BMDL. BMD ¼ benchmark dose, BMDL ¼ benchmark dose lower bound, BMDS ¼ benchmark dose software, BMR ¼ benchmark
response
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selected for this factor. Although the data selected for the POD
were derived from a subchronic study of 20 weeks, the selected
endpoint for the critical effect is not a toxic manifestation, but
rather a precursor that occurs at both lower doses and earlier
time points compared to the ﬁnal toxic manifestation of tumor
formation. Given that longer exposures to similar doses of
alpha-HCH have not been shown to manifest toxic lesions in
mice or rats, this precursor event is considered to be a conser-
vative basis for the toxicity criterion and intended to be pro-
tective against cancer effects. Therefore, no UF to account for
effects seen at less than chronic durations was applied.
 LOAEL-to-NOAEL Factor e A value of 1 was selected for this
factor, as the ﬁnal POD was not based on a LOAEL but rather a
BMDL.
 Database Uncertainty Factor e A value of 1 was selected for
this factor, as the available database was considered complete.
Signiﬁcant data gaps that would affect the determination of the
critical effect and the POD for that critical effect were not
identiﬁed. Additional Modifying Factors e No additional modifying fac-
tors were determined to be necessary for the derivation of the
RfD.3.2.5. Alpha-HCH RfD
Based on the MOA evaluation and dose-response evaluation
presented, we recommend an RfD for alpha-HCH of 0.002 mg/kg-
day. The value is based on a POD of 0.061 mg/kg-day for develop-
ment (incidence and size) of preneoplastic hepatic foci in rats, and a
combined UF of 30 (10 for intraspecies extrapolation and 3 for
interspecies extrapolation).
4. Discussion and conclusions
We completed an MOA evaluation and dose-response assess-
ment for alpha-HCHeinduced liver carcinogenesis and developed a
supportable toxicity criterion for the protection of human health in
line with established guidelines and published frameworks (e.g.,
USEPA, 2005; Meek et al., 2003). We conclude that the WOE
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tumors in rats and mice through an MOA involving increased
promotion of cell growth, or mitogenesis. The key events under-
lying its carcinogenic action are: (1) absorption of alpha-HCH in the
liver, (2) P450 induction via receptor-mediated mechanisms, (3)
increased cell proliferation, ultimately resulting in (4) benign and
malignant tumor formation. Although the human relevance of this
MOA remains a matter of scientiﬁc debate, EPA currently treats
alpha-HCH as a human carcinogen to regulate human exposures.
The nonlinear RfD for alpha-HCH that we established in this
paper of 0.002 mg/kg-day is approximately 100 to 10,000 times
greater than the risk speciﬁc dose (RSD) values corresponding with
EPA's IRIS excess cancer risks of 104 and 106, respectively.
Although U.S. regulatory policy suggests that there are different
deﬁnitions of what constitutes de minimis risk, in general, the point
of little-to-no concern is at the 106 risk level, ranging upward to
104, which corresponds to EPA's target risk range in the
Comprehensive Environmental Response, Compensation, and Lia-
bility Act program, under the National Oil and Hazardous Sub-
stances Pollution Contingency Plan, (also known as the National
Contingency Plan). Environmental standards established upon the
basis of risk would thus be several orders of magnitude higher than
those currently employed based on a linear cancer model should
the resultant RfD established here be applied.
Although sufﬁcient data are available to demonstrate that
alpha-HCH is a rodent carcinogen that operates via a threshold
based mechanism/MOA there are some uncertainties in the un-
derlying toxicological studies (Table 1) that could be reduced with
further study. Studies investigating gene expression for alpha-HCH
alongside other known CAR and PXR inducers would help to bolster
the deﬁned MOA. Studies measuring early indicators of tumor
formation in rodents, including foci growth, would help to reduce
uncertainties in the RfD established. Further, additional data to help
establish the human relevance of CAR and PXR induced effects for
alpha-HCH along with other similarly acting chemicals would help
to informwhether this compound should be regarded as a potential
human carcinogen and address the on-going scientiﬁc debate
regarding the signiﬁcance of cancers mediated via receptor medi-
ated mechanisms (Elcombe et al., 2014; Hall et al., 2012).
Exposure to alpha-HCH is of continuing concern due to the
historical levels of HCH use, and its persistence in the environment.
EPA recently included alpha-HCH on the CCL4 (USEPA, 2015a) and
proposed it for inclusion in the 4th UCMR program (USEPA, 2015b),
suggesting the possibility that alpha-HCH may require regulation
under the SWDA in the future. Given the regulatory focus on alpha-
HCH regulatory agencies should review the scientiﬁc evidence that
supports treating alpha-HCH as a threshold based toxicant.
Precedent for establishing threshold based criteria for evaluating
the carcinogenicity of a compound based on the compound's MOA
and EPA's cancer guidelines (USEPA, 1996, 2005) exists. EPA uses a
nonlinear, threshold approach for characterizing cancer risks to
chloroform (USEPA, 2001, 2015b) based on the compound's MOA.
TheWOE supports that chloroform does not produce rodent tumors
via a mutagenic MOA, but rather carcinogenic responses observed
in animals are associated with regenerative hyperplasia that occurs
in response to cytolethality and cytolethality occurs only at expo-
sure levels above some critical dose level (USEPA, 2001). Also based
on the compounds' MOAs, EPA has determined that a threshold for
carcinogenicity exists for captan (69 Fed. Reg. 68357) and ethylene
glycol monobutyl ether (EGBE) (USEPA, 2010, 2015c).Acknowledgments
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